Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
FranceIPO:
27 March 2019Website:
http://www.genfit.comNext earnings report:
04 April 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 03 Oct 2024 20:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
GNFT Latest News
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH1 in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
The U.S. Food and Drug Administration has approved French drugmakers Ipsen and Genfit's drug to treat a chronic inflammatory liver disease, Ipsen said on Monday.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 22, 2024. The quorum on first convening amounted to 27.25% and shareholders approved all of the resolutions.
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present an update on its scientific and corporate progress at The Liver Meeting® 2023 organized by the American Association for the Study of Liver Diseases (AASLD), which will take place in Boston, MA (USA) from November 10-14, 2023.
Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) , September 05 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences.
GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational therapeutic elafibranor in patients with the rare cholestatic liver disease primary biliary cholangitis (PBC). The two companies announced on Friday that the Phase 3 ELATIVE trial met its primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to the placebo.
The U.S.-listed stock of Genfit S.A. GNFT, -5.48% GNFT, +22.56% soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEY, +7.22% IPN, +0.27% announced positive results from a late-stage trial of a treatment for a rare liver disease.
What type of business is Genfit SA?
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
What sector is Genfit SA in?
Genfit SA is in the Healthcare sector
What industry is Genfit SA in?
Genfit SA is in the Biotechnology industry
What country is Genfit SA from?
Genfit SA is headquartered in France
When did Genfit SA go public?
Genfit SA initial public offering (IPO) was on 27 March 2019
What is Genfit SA website?
https://www.genfit.com
Is Genfit SA in the S&P 500?
No, Genfit SA is not included in the S&P 500 index
Is Genfit SA in the NASDAQ 100?
No, Genfit SA is not included in the NASDAQ 100 index
Is Genfit SA in the Dow Jones?
No, Genfit SA is not included in the Dow Jones index
When was Genfit SA the previous earnings report?
No data
When does Genfit SA earnings report?
The next expected earnings date for Genfit SA is 04 April 2025